National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
NCI Home Cancer Topics Clinical Trials Cancer Statistics Research & Funding News About NCI
Cyclooxygenase (COX) Inhibitors
    Posted: 02/15/2005



Links to NCI Materials







Links to Other Materials






Current Clinical Trials



Page Options
Print This Page  Print This Page
Print This Document  Print This Document
View Entire Document  View Entire Document
E-Mail This Document  E-Mail This Document
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

Español
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate

New Study of Targeted Therapies for Breast Cancer

The Nation's Investment in Cancer Research FY 2009

Cancer Trends Progress Report: 2007 Update

Past Highlights
You CAN Quit Smoking Now!
Related Pages
Colon and Rectal Cancer Home Page
NCI's gateway for information about colon and rectal cancer.

Search for Clinical Trials
NCI's PDQ® registry of cancer clinical trials.
Links to Other Materials

FDA Issues Public Health Advisory Recommending Limited Use of Cox-2 Inhibitors
On Dec. 23, 2004, the U.S. Food and Drug Administration (FDA) issued a Public Health Advisory summarizing the agency's recommendations concerning the use of non-steroidal anti-inflammatory drug products (NSAIDs), including those known as COX-2 selective agents.

< Previous Section  |  Next Section >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov